טוען...
A Real Life Experience with the Comsos Regimen in Genotype 1 Chronic Hepatitis C Treatment: Including Patients with East Asian Ancestry and Decompensated Cirrhosis
BACKGROUND/AIMS: The COMSOS phase 2 trial showed high cure rates and a favorable side effect profile of a 12-week regimen of Sofosbuvir (SOF) and Simeprevir (SIM) in patients with a genotype 1 Hepatitis C infection. However, given the small number of patients in the COSMOS trial, there is uncertaint...
שמור ב:
| הוצא לאור ב: | Hawaii J Med Public Health |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
University Clinical, Education & Research Associate (UCERA)
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4582373/ |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|